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SUMMARY
The biological and clinical behaviors of hematological malignancies can be influenced by the active crosstalk
with an altered bone marrow (BM) microenvironment. In the present study, we provide a detailed picture of
the BM vasculature in acute myeloid leukemia using intravital two-photon microscopy. We found several ab-
normalities in the vascular architecture and function in patient-derived xenografts (PDX), such as vascular
leakiness and increased hypoxia. Transcriptomic analysis in endothelial cells identified nitric oxide (NO) as
major mediator of this phenotype in PDX and in patient-derived biopsies. Moreover, induction chemotherapy
failing to restore normal vasculature was associated with a poor prognosis. Inhibition of NO production
reduced vascular permeability, preserved normal hematopoietic stem cell function, and improved treatment
response in PDX.
INTRODUCTION
Acute myeloid leukemia (AML) is the most common acute leuke-
mia in adults (Sant et al., 2010). AML is a hematological malig-
nancy arising from the occurrence of genetic mutations in
hematopoietic progenitors, which cause a blockage in the matu-
ration and an uncontrolled growth of leukemic blasts in the bone
marrow (BM). While the clinical presentation of AML is quite
uniform, it is a highly heterogeneous disease at the molecular
level. There is a consistent effort aimed to characterize each
molecular subgroup and design the best therapeutic strategy
(Grimwade et al., 2010). Besides a few cases (Wang and Chen,
2008), the common clinical practice remains induction therapy
with cytarabine (AraC) (Buchner et al., 2012; Mayer et al.,
1994). However, therapy resistance and relapse remain a major
clinical challenge.
Another approach aims to identify and target common fea-
tures within this complex disease. One possibility could be the
BM microenvironment, which is the site where leukemic cells
arise, expand, and eventually develop resistance to therapy.
The BM microenvironment is constituted by different types of
cells, with a predominant vascular component responsible for
nutrient and metabolite turnover, the ingress and egress of
different cells, and the regulation of normal hematopoietic
Significance
Acute myeloid leukemia (AML) represents the most common acute leukemia affecting adults. Recent findings suggest that
AML cells alter their microenvironment, which represents an intriguing source of potential therapeutic targets. A thorough
characterization of the vasculature of the bonemarrowwith AML reveals a severe functional abnormality. Vascular wall bar-
riers responsible for oxygen, nutrients, and drug delivery appear severely damaged, with increased permeability, altered
perfusion, and release of normal hematopoietic stem cells to the periphery. At a molecular level, endothelial cell signature
is altered, resulting in increased reactive oxygen species and nitric oxide. In our preclinical models, the successful combi-
nation of nitric oxide synthase inhibitors and chemotherapy restore normal vasculature and delay leukemia, leading the way
to combine leukemia-niche therapies in clinical trials.
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stem cell (HSC) function (Boulais and Frenette, 2015; Mendez-
Ferrer et al., 2015). The introduction and development of
intravital two-photon (2P) microscopy has allowed direct, high-
resolution, dynamic imaging of the calvarium BM (Colmone
et al., 2008; Foster et al., 2015; Lassailly et al., 2013; Lo Celso
et al., 2009; Sipkins et al., 2005), providing a powerful tool for
the functional characterization of the BM microenvironment.
Recent findings indicate that myeloid malignancies also affect
the function of the BM niche, pointing to the existence of an
active crosstalk between leukemic cells and the microenviron-
ment (Dong et al., 2016; Frisch et al., 2012; Hanoun et al.,
2014; Kim et al., 2008; Kode et al., 2014; Krause et al., 2013;
Raaijmakers et al., 2010; Schepers et al., 2013; Schmidt et al.,
2011; Zhang et al., 2012). Similar to what has been observed in
solid cancers, AML has been associated with an increase in
microvascular density (MVD) and production of pro-angiogenic
factors, notably vascular endothelial growth factor (VEGF)
(Chand et al., 2016; Hussong et al., 2000; Kampen et al.,
2013). However, whether increased MVD and VEGF constituted
a prognostic factor for AML treatment response remains unclear
(Aref et al., 2005; Padro et al., 2000; Reddy and Moreb, 2000).
Moreover, despite promising preclinical studies (Zhu et al.,
2003), clinical trials incorporating anti-VEGF inhibitors have not
produced encouraging results (Fiedler et al., 2003, 2005; Giles
et al., 2006; Mattison et al., 2015; Roboz et al., 2006; Zahiragic
et al., 2007), suggesting that targeting pro-angiogenic cytokines
may not be the best strategy for disrupting the crosstalk between
AML and the vascular niche. A thorough analysis of the status of
the vasculature in the BM is required to dissect the complexity of
the vascular phenotype associated with AML. Thus, we aim to
study the in vivo picture of the abnormalities associated with
the BM vasculature induced by AML engraftment and unravel
common pathologic processes, which could represent potential
targets in AML.
RESULTS
AML Engraftment Alters Vascular Architecture and
Function
To provide a detailed picture of the BM vasculature in AML, we
studied the status of the vascular niche in human AML patient-
derived xenografts (PDX). Recipient mice were left uncondi-
tioned, given the toxic effect derived from the irradiation or
myelosuppressive treatment on the vasculature (Hooper et al.,
2009; Kopp et al., 2005; Shirota and Tavassoli, 1991; and data
not shown). We observed an expansion of the endothelial
compartment among the non-hematopoietic stroma upon hu-
man AML engraftment (Figure 1A and Table 1). Importantly,
this effect was specific to AML, as no such expansion was
observed in mice engrafted with normal human hematopoietic
stem/progenitor cells (HSPCs) derived from umbilical cord blood
(CB) (Figure 1A). Moreover, the percentage of endothelial cells
(ECs) was positively correlated to the leukemic engraftment of
human AML cell lines and patient-derived samples (Figure S1A),
suggesting a gradual pathologic process. Not only did the per-
centage of ECs increase, but there was also a real expansion
of the endothelial compartment in terms of absolute number,
specifically upon human AML engraftment (Figure 1B). We also
observed an increased MVD, as shown by the higher number
of vessel sprouts quantified by immunofluorescence (Figures
S1B and S1C), similar to what is observed in patient-derived tre-
phines (Chand et al., 2016; Padro et al., 2000). The existence of
Figure 1. AML-Derived Alteration of the BM Vascular Architecture and Function
(A) Quantification of CD31+ ECs in the BM (shown as percentage of CD45-Ter119- BM cells) of non-transplanted mice (ctrl) and mice transplanted with HSPCs
(CB) or AML patient-derived samples, as depicted. Each dot represents an individualmouse. Ctrl, n = 22; CB, n = 29; AML patients (AML1, 2, 3, 5, 6, 7, 8, 9), n = 30.
Data are shown as mean ± SEM.
(B) Absolute number of CD31+ ECs in the BM (2 femurs, 2 tibias, and 2 iliac crests) of non-transplanted mice (ctrl) and mice transplanted with CB-derived HSPCs
(CB) or AML patient-derived samples, as depicted. Each dot represents an individual mouse. Ctrl, n = 17; CB, n = 26; AML patients (AML1, 2, 6, 7, 8, 9), n = 23.
Data are shown as mean ± SEM.
(C) Frequency of Sca-1high and Sca-1low CD31+ cells in the BM of non-transplanted mice (ctrl) and mice transplanted with AML patient-derived samples. Ctrl,
n = 19; AML patients (AML 2, 3, 6, 8, 9), n = 16. Data are shown as mean ± SEM.
(D) Representative 3D reconstruction of BM vasculature of the calvarium of non-transplanted mice (ctrl) and mice transplanted with CB-derived HSPCs (CB) or
AML patient-derived samples, as depicted, imaged via 2Pmicroscopy 1min after injection of 655-conjugated NT-Qtracker as vessel-pooling agent. White arrows
pointing at sinusoids. Data are representative of triplicates in 4 independent experiments. Scale bars represent 70 mm.
(E) Quantification of vascular mean diameter in the calvarium BM of non-transplanted mice (ctrl) and mice transplanted with CB-derived HSPCs (CB) or human
AML-derived samples, as depicted, using IMARIS filament tool. Dots represent the diameter of vascular fragments in the z stack of the calvarium of at least 3mice
per group. Ctrl, n = 235; CB, n = 232; HL60, n = 91; ML1, n = 148; U937, n = 85; AML6, n = 130; AML8, n = 94. Red lines represent the mean ± SEM.
(F) Representative 3D reconstruction of BM hypoxia imaged via intravital microscopy using the HypoxiSense probe together with vasculature (dextran) and
Nestin+ cells in non-transplanted mice or mice transplanted with AML6 patient-derived cells, as depicted. Scale bars represent 50 mm.
(G) Distribution and relative frequency of vessel distances to hypoxic areas in the BM of non-transplanted mice (ctrl) or mice transplanted with AML6 patient-
derived cells, as depicted.
ns, not significant; *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1.
Table 1. Patient-Derived Samples Used for Xenograft Studies
AML ID Cytogenetics Cyto Risk NPM FLT3
AML1 NDa ND mutant ND
AML2 t(9,6) intermediate ND ND
AML3 normal intermediate WT ITDb
AML4 11q23/MLL ND ND ND
AML5 complex poor WT ND
AML6 normal intermediate mutant ITD
AML7 normal intermediate mutant ITD
AML8 Del 7q+8 + 1 poor WT WT
AML9 normal intermediate mutant ITD
AML10 complex poor ND ND
aNot determined.
bInternal tandem duplication.
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specific endothelial cell markers defining distinct BM vascular
niches has recently been highlighted (Itkin et al., 2016). We
thus analyzed the expression of these markers in the context
of AML disease in PDX. We observed a significant loss of ECs
associated with sinusoids (CD31+Sca1low) as well as an
increased number of ECs associated with arterioles (CD31+
Sca1high) (Figures 1C and S1D). We next analyzed the architec-
ture of the BM vasculature by 2P microscopy using a vessel-
pooling agent to visualize the vascular tree in the calvarium
BM. Although vascular architecture appeared highly heteroge-
neous among different PDX (Figures 1D and S1E), we noticed
some common abnormalities. First, the regularity of sinusoidal
structures, which are preservedwith normal human engraftment,
was lost in human AML xenografts (Figure 1D, white arrows
pointing at sinusoids). Second, the mean vascular diameter of
vessels was reduced (Figure 1E), a pathologic phenotype previ-
ously reported in tumor angiogenesis as a result of solid stress
applied to vessels by overgrowing tumor cells (Padera et al.,
2004; Stylianopoulos and Jain, 2013). Vessel compression was
also highlighted by H&E staining in long bones (Figure S1F,
dashed circles indicating vessel lumen). To study BM perfusion,
we injected isolectin B4 (IB4), a pan-endothelial marker (Lassailly
et al., 2013), and analyzed its distribution on the BM vasculature
by 2Pmicroscopy. In control mice, we observed a homogeneous
IB4 perfusion rate, allowing the visualization of ECs surrounding
the arteriolar and sinusoidal vasculature (Figure S1G, ctrl). In
contrast, we observed the presence of many poorly perfused
areas in the BM of AML xenografts (Figure S1G). We next tested
whether AML engraftment also affected BM oxygenation, by
measuring the BM hypoxia. While in non-transplanted mice we
observed a heterogeneous staining with Hypoxyprobe, indi-
cating a physiological spread distribution of hypoxic areas, hu-
man AML engraftment increased the hypoxia homogeneously
throughout the bones (Figure S1H). Quantification of Hypoxyp-
robe staining in BM cells by flow cytometry confirmed the signif-
icant increase of BM hypoxia upon human AML engraftment
compared with normal human engraftment (Figure S1I). Of
note, at early stage of engraftment hypoxia was localized in close
proximity to AML cells (Figures S1J–S1M), whereas at high
engraftment the BM was overall hypoxic (Figures S1N–S1P).
We next visualized the hypoxic state of the BM via intravital mi-
croscopy using HypoxiSense probe (Bao et al., 2012). Similar to
what was observed with Hypoxyprobe, we observed increased
hypoxia in the BM upon AML engraftment with this alternative
method (Figures 1F, S1Q, and S1R). To evaluate the hypoxic
state of the vasculature, we measured the distance of each
vessel to hypoxic areas. Whereas in control BM this distance
was widely distributed, in the presence of AML most of the ves-
sels were close to hypoxic areas (Figures 1G and S1S). Together
these results showed that AML is associated with a structurally
and functionally abnormal vasculature in the BM.
AML Engraftment Increases Vascular Permeability in
the BM
To study the vascular barrier function in the BM of human AML
xenografts, we used intravital 2P microscopy to image the
calvarium of unconditioned NSG mice engrafted with different
human AML cell lines or patient-derived samples. Human AML
cell lines were engineered to express GFP and luciferase to facil-
itate the monitoring of BM engraftment via bioluminescence
(Figure S2A) and BM aspirate (Figure S2B). Prior to imaging,
tetramethylrhodamine isothiocyanate (TRITC)-dextran was in-
jected intravenously to label the vasculature (Egawa et al.,
2013; Fukumura and Jain, 2008) (Figure 2A). Strikingly, we
observed an important leakage of the dextran outside the vascu-
lature in the BM of mice engrafted with human AML cell lines
compared with control non-transplanted mice (Figures 2B and
S2C). This observation was corroborated by H&E staining of
long bones showing the loss of vascular barriers and release of
erythrocytes in the BM parenchyma (Figure S2D, red arrows
pointing at erythrocytes). To quantify the vascular leakiness,
we used a strategy allowing reliable measurement independent
of the fluorescence intensity of the probe (detailed in Figure S2E
and STAR Methods). The intravital observation of the calvarium
BM vasculature at different time points after injection of the
vessel-pooling agents showed an increased vascular leakiness
starting between 6 and 9 min post injection (Figure 2C). We
quantified vascular permeability in xenografts of different human
AML samples 10 min after injection of the vessel-pooling agents
(Figures 2D and 2E). All the samples used in our study, which
represented different molecular subtypes of human AML,
induced increased vascular leakiness in the BM. A different
method using in vivo Hoechst permeability in BM cells (Wong
et al., 2015) was used to confirm the AML-associated vascular
phenotype in the BM (Figures S2F and S2G). Of note, AML-
engrafted areas appeared to be much more leaky than
Figure 2. AML Engraftment Increases Vascular Permeability in the BM
(A) Schematic of the experiment. Human AML cells engineered to express GFP and luciferase were injected intravenously into NSG mice and engraftment was
monitored via bioluminescence and BM aspirate. Once engraftment was confirmed, 3 mg of 65–85 kDa TRITC-dextran was injected intravenously and 15 min
later, calvaria were imaged via 2P microscopy.
(B) Representative z stack of the TRITC-dextran-labeled BM vasculature in the calvarium of non-transplanted control or from mice transplanted with GFP-HL60
cells. Left: TRITC-dextran signal alone. Right: merge of TRITC-dextran and GFP signals. Data are representative of triplicates. Scale bars represent 30 mm.
(C) Vascular leakiness quantified in vivo at different time points after dextran injection in non-transplanted mice (ctrl) and U937 or AML6 patient cells-en-
grafted mice.
(D) Vascular leakiness quantification in the BMof non-transplantedmice ormice transplanted with different humanAML cell lines and patient-derived samples, as
depicted, and imaged 10min after administration of vascular dyes. Ctrl, n = 11; CB, n = 19; HL60, n = 12;ML1, n = 7; U937, n = 4; AML9, n = 6; AML6, n = 14; AML5,
n = 4; AML1, n = 12; AML3, n = 4; AML2, n = 3; AML8, n = 7; AML7, n = 6. Data are shown as whiskers minimum-to-maximum plots, the line inside the box
representing themean, the top and the bottom lines representing the 75%and 25%percentiles, respectively, and the lines above and below the box representing
the SD.
(E) Representative z stacks of BM vasculature in the calvarium of non-transplanted mice (ctrl) or mice engrafted with HL60 or AML9 cells, as depicted. Scale bars
represent 80 mm.
ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2.
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(B) Representative 3D reconstruction of the BM vasculature in the calvarium of mice engrafted with different patient-derived samples treated with solvent (top) or
AraC (bottom). Scale bars represent 70 mm.
(C) Vascular leakiness in the BMofmice transplanted with different human AML patient-derived samples, treatedwith solvent or AraC, as depicted. Three ormore
replicates were used for each condition. Data are shown as whiskers minimum-to-maximum plots, the line inside the box representing the mean, the top and the
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non-engrafted areas (Figures S2H and S2I). In normal BM,
Nestin-associated vessels, characterized by higher expression
of Sca-1 (Itkin et al., 2016), show less permeability than Nestin
vessels (Figure S2J). On the contrary, in the presence of
leukemic engraftment, both Nestin+ and Nestin vessels were
associated with increased leakiness (Figures S2J and S2K),
highlighting a substantial functional difference between normal
and leukemic Nestin-associated Sca-1+ vessels. Of note, reduc-
tion of normal pericyte coverage was also observed in the BM of
AML PDX (Figure S2L). These results show an altered vascular
permeability in the BM associated with AML engraftment,
observed commonly throughout different AML subtypes.
Chemotherapy Does Not Rescue Normal Vascular
Permeability in the BM
It is still debated whether AML-derived angiogenesis, in terms of
MVD in the BM and VEGF quantification, is reduced in patients
upon chemotherapy (Aref et al., 2005; Chand et al., 2016; Padro
et al., 2000; Reddy and Moreb, 2000). Thus, we analyzed the
level of VEGF in BM biopsies obtained at diagnosis and post
treatment from a cohort of AML patients (Tables S1 and S2).
We found an increase in VEGF in the majority of patients’ post-
treatment biopsies (Figures S3A and S3B). This suggests a
persistent pro-angiogenic environment after chemotherapy.
We thus studied the vascular niche state in AML PDX after
chemotherapy. We set up a preclinical treatment protocol, which
closely followed the clinical practice, by treating AML xenotrans-
plantedmice daily with 10mg/kg of AraC during one or two alter-
nate weeks, depending on xenografts’ response (Figure 3A). This
treatment significantly reduced the leukemic burden in the BM
(Figure S3C) and induced a ‘‘remission-like’’ phase, during which
the remaining leukemic cells persist and give rise to relapse after
few weeks (not shown). Notably, residual AML cells after AraC
treatment localized in close proximity to the vasculature (Fig-
ure S3D). We observed the BM vasculature with 2P microscopy
during the ‘‘remission-like’’ phase in different cohorts of AML
PDX treated with this protocol. Although the leukemic engraft-
ment was significantly reduced, the vascular permeability was
still very high, similar to mice treated with the control solvent,
which were highly engrafted with leukemic cells (Figures 3B
and 3C). Moreover, the number of ECs was not reduced in
AML PDX after AraC treatment (Figure 3D), suggesting that the
abnormal vascular phenotype was maintained. This effect was
not due to an unspecific toxicity of the chemotherapy on the
vascular niche, as non-transplanted mice or mice engrafted
with normal HSPCs and subjected to the same treatment did
not show abnormal vascular permeability (Figures S3E and
S3F), frequency, or number of ECs in the BM (Figures S3G and
S3H). These results show that in AML disease, the vascular bar-
rier functionality is still compromised after chemotherapeutic
treatment. Furthermore, we observed that BM hypoxia was not
normalized upon removal of leukemic cells (Figures 3E and 3F).
Notably, similarly to what was observed in presence of high
leukemic infiltration, most of the vessels were still close to hyp-
oxic areas upon AraC treatment (Figure 3G). These data highlight
a persistent poorly functional vasculature in the BM of AML PDX
after chemotherapy.
AML-Induced Molecular Signature in Vascular ECs
AML cells have been extensively studied at the transcriptional
level, with many reports assessing the production of angiogenic
factors (Aref et al., 2002; Hatfield et al., 2009; Ribatti et al.,
2007). To identify common downstream effectors of this angio-
genic stimulation in the vascular niche, we studied the tran-
scriptome of BM-derived ECs retrieved from mice engrafted
with different AML patient-derived cells via RNA sequencing
(RNA-seq), and compared it with ECs retrieved from non-en-
grafted mice or mice engrafted with normal HSPCs. As shown
by the hierarchical clustering, despite the heterogeneity found
among the groups, we identified a common deregulated signa-
ture associated with human AML engraftment (Figure 4A). Gene
set enrichment analysis (GSEA) highlighted several altered pro-
cesses directly associated with the abnormal vascular pheno-
type observed above, including vasculature development,
angiogenesis, and response to hypoxia (Figure 4B). Several de-
regulated pathways associated with angiogenic and hypoxic
stimulation were identified (Figures 4B and S4A). Interestingly,
the expression of adhesion molecules changed dramatically
upon AML engraftment, with upregulation of integrins associ-
ated with Fak pathway activation in ECs (Figure S4B) inducing
migration, growth, and survival of newly forming vessels during
angiogenesis (Muether et al., 2007; Stenzel et al., 2011; Weis
and Cheresh, 2011), as well as initiation of VEGF-mediated
vascular permeability (Chen et al., 2012; Eliceiri et al., 2002;
Rodrigues and Granger, 2015). We noticed also reduced
expression of tight junction components, e.g., Cldn1 respon-
sible for maintaining endothelial layer integrity (Rodrigues and
Granger, 2015) or Vcam1 required for HSC homing and reten-
tion to the niche (Lewandowski et al., 2010; Ulyanova et al.,
2007). Interestingly, we found among the common highest up-
regulated genes in ECs upon AML engraftment Nox4, a NAPDH
oxidase expressed in the vasculature and involved in the
response to hypoxia via production of reactive oxygen species
(ROS), activation of nitric oxide synthase 3 (NOS3), and release
of nitric oxide (NO) (Craige et al., 2011) (Figure 4C). Of note, in
response to AML engraftment, Nox4 expression in ECs (Fig-
ure 4D) and ROS production in the BM (Figure 4E) were both
increased. Moreover, the upregulated expression of Nox4 in
ECs and the high production of ROS in the BM were maintained
after AraC treatment (Figures 4F and 4G). These data show that
the AML-induced hypoxic environment alters the molecular
signature of vascular ECs, activating several pro-angiogenic
n = 16. Data are shown as whiskers minimum-to-maximum plots, the line inside the box representing the mean, the top and the bottom line representing the 75%
and 25% percentiles, respectively, and the lines above and below the box representing the SD.
(F) Representative 3D reconstruction of BM hypoxia imaged via intravital microscopy using the HypoxiSense probe together with vasculature (dextran) and
Nestin+ cells in mice transplanted with AML6 patient-derived cells and treated or not with AraC, as depicted. Scale bars represent 50 mm.
(G) Distribution and relative frequency of vessel distances to hypoxic areas in the BMofmice transplanted with AML6 patient-derived cells, and treated or not with
AraC, as depicted.
ns, not significant; **p < 0.01. See also Figure S3; Tables S1 and S2.
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Figure 4. AML-Induced Transcriptional Signature in BM ECs
(A) Heatmap from hierarchical clustering of GSEA top 100 ranked genes between untransplanted mice (ctrl group), mice engrafted with human CB-derived
HSPCs (CB group), and mice engrafted with different patient-derived samples (AML group) derived BM ECs, using RNA-seq data. Red indicates higher
expression values and blue indicates lower expression values (log2 FPKM [fragments per kilobase per million mapped] scale).
(B) Enrichment plots for Processes (top) and Pathways (bottom) from GSEA between CB and AML groups using RNA-seq gene expression data indicate
enrichment of these pathways in AML group. Normalized enrichment score (NES) and nominal p value are shown.
(C) Normalized expression values of Nox4 in CB versus AML groups analyzed via RNA-seq. Data are shown as whiskers minimum-to-maximum plots, the line
inside the box representing the mean, the top and the bottom lines representing the 75% and 25% percentiles, respectively, and the lines above and below the
box representing the SD.
(D) Nox4 expression analyzed by qRT-PCR in CD31+ BM cells retrieved from the depicted groups of mice. CB, n = 5; AML cell lines, n = 8; AML patients (AML1,
2, 9), n = 13. Data are shown as mean ± SEM.
(E) Cellular ROS levels in BMC retrieved from mice of depicted groups; n = 3 per group. Data are shown as mean ± SEM.
(F) Nox4 expression analyzed by qRT-PCR in CD31+ BM cells retrieved from mice engrafted with AML6 and treated or not with AraC. n = 3 per group. Data are
shown as mean ± SEM.
(G) Cellular ROS levels in BMC retrieved from mice engrafted with AML6 and treated or not with AraC; n = 3 per group. Data are shown as mean ± SEM.
ns, not significant; *p < 0.05, **p < 0.01. See also Figure S4.
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pathways and positively regulating Nox4 expression and the
response to hypoxia.
AML Engraftment Is Associated with Increased Nitric
Oxide Levels in the BM
As NO is the major mediator of vascular permeability in both
physiological and several pathological conditions (Aramoto
et al., 2004; Fukumura et al., 2001, 2006; Mayhan, 1999), we
investigated whether the AML-derived upregulation of Nox4 in
ECs influenced NO production in the BM vascular niche. We
found increased levels of NO in the BM of AML xenografts
compared with non-transplanted mice or mice engrafted with
normal HSPCs (Figure 5A). A slight but significant increase of
NO levels was also observed in BM of PDX with low engraftment
(not shown). This effect seemed to be specific to BM (Fig-
ure S5A). Of note, as already observed for vascular permeability
and Nox4 expression in ECs, chemotherapy failed to normalize
the NO levels in the BM of AML PDX (Figure 5B).
To translate our observations to the human disease, we
analyzed the NO levels in our cohort of AML patient-derived
BM biopsies and compared them with those of healthy donors
(Tables S1 and S2). We observed a significant increase in the
NO level in BM aspirates of patients at diagnosis, which were
similar to those observed in xenografts, compared with healthy
donors (Figure 5C). NO levels were higher in the BM compared
with the blood of the same patient at diagnosis (Figure S5B),
similar to what was observed in mice with AML xenografts.
Importantly, also similar to what was observed in AML xeno-
grafts, the NO levels remained elevated in the majority of post-
treatment BM samples analyzed (Figures 5D and 5E). Moreover,
failure in reducing NO levels appeared to be associated with a
higher incidence of treatment failure (Figure S5C), with a proba-
bility of 73% in the cohort of patients studied herein (Figure S5D).
This probability increases to 100% if we restrict the analysis to
the intermediate-risk group samples, characterized by a more
controversial prognostic assessment (Figure S5E). Our data sug-
gest that persistence of high NO levels in the BM of patients after
therapy could represent a biomarker for poor prognosis, partic-
ularly in patients with intermediate-risk AML. The upregulation of
Nox4 in ECs, indicating an overactivation of NOS3 in this
compartment, likely is responsible for the increased NO levels
in the BM. We therefore analyzed the expression of NOS3 in
the two major components of the vascular niche, endothelial
(CD31+) and mesenchymal perivascular (Nestin+) cells (Fig-
ure S5F). We observed that ECs represented the major compart-
ment expressing NOS3 both at mRNA (Figure S5G) and protein
(Figure 5F) levels. Moreover, we observed that NOS3 protein
expression was significantly increased in ECs retrieved from
mice engrafted with human AML patient-derived samples (Fig-
ure 5G). Of note, not only the total NOS3 protein level but also
its activation was increased, as shown by increased phosphory-
lation of Ser1177 (Figure 5H (Kolluru et al., 2010)). In contrast,
NOS3 was not increased in the mesenchymal compartment
upon AML engraftment (Figure S5H). NOS2 protein expression
is not changed in either the endothelial or the mesenchymal
compartment upon AML engraftment (Figure S5I). Analysis of
different endothelial subpopulations revealed that in normal
BM, CD31+Sca-1high ECs exhibit lower ROS and NO levels
than CD31+Sca-1low ECs (Figure 5I), and AML engraftment
caused an increase in both ROS and NO levels in the CD31+
Sca-1high population (Figure 5J). We investigated the conse-
quences of long-term higher production of NO and ROS in
ECs, and observed that in heavily engrafted AML xenografts
ECs displayed increased apoptosis in both Sca-1high and
Sca-1low ECs (Figure S5J), whereas cell-cycle arrest was
restricted to the Sca-1high EC fraction (Figure S5K).We next eval-
uated whether the leukemic compartment might also contribute
to the NO overproduction. Human AML cells do not express
higher mRNA levels ofNOS2 orNOS3 compared with normal he-
matopoietic cells residing in the BM, as reported in publicly avail-
able datasets (HemaExplorer/BloodSpot, not shown). Moreover,
the mRNA levels of these enzymes in AML patient-derived sam-
ples were similar to those from healthy donors (Figures S5L and
S5M). There was no significant upregulation of these enzymes
after chemotherapy (Figures S5N and S5O), or in AML xenografts
(P1) compared with their primary counterpart (P0) (Figure S5P).
The NOS3 protein level in AML was much lower than that in
the endothelial compartment (Figure S5Q). Our results show an
overproduction of NO in the BM in the presence of AML at diag-
nosis as well as after therapy, produced by an abnormally acti-
vated NOS3 in BM ECs.
Targeting Vascular Permeability Cooperates with
Chemotherapy to Improve AML Treatment Response
To test whether the exogenous production of NO has a role in
leukemia transplantation and progression, we transplanted
leukemic cells from two models of murine AML (MLL-AF9 and
MLL-ENL) in Nos3-knockout (Nos3-KO) recipient mice and
studied the status of the vasculature and disease progression.
Interestingly, MLL-AF9 leukemia occurrence was significantly
delayed in Nos3-KO mice (Figure S6A, top), Nos3-KO mice
were active and healthy at the time wild-type (WT) mice showed
clear signs of disease and were euthanized. Similar results were
obtained using two distinct clones of MLL-ENL AML trans-
planted in WT or Nos3-KO recipient mice, showing significantly
reduced disease penetrance (Figure S6A, bottom), reduced
leukemic engraftment in the BM and spleen (Figures S6B and
S6C), and amelioration of the anemic phenotype caused by
AML (Figure S6D). Moreover, Nos3 inactivation cooperated
with AraC treatment to reduce leukemic engraftment in both
MLL-AF9 and MLL-ENL models (Figure 6A) and reduced the
vascular leakiness in the BM of AML-engrafted mice (Figure 6B).
Together these data suggest that exogenous NO production by
NOS3 has a role in AML engraftment. We next investigated
whether the observed difference was likely to be attributed to a
delay in engraftment or also to a reduction in disease progres-
sion. For that we used the PDX model and allowed AML cells
to engraft the animals before inhibiting NO production with
NOS inhibitors. We set up a similar treatment strategy to the
one used before, including NOS inhibitors during and after the
chemotherapy, to normalize the vascular permeability (Fig-
ure 6C). Treatment of mice xenografted with human ML1 cell
line with NOS inhibitors in combination with chemotherapy
significantly inhibited leukemic progression, as shown by
reduced number of leukemic cells in the BM and the spleen (Fig-
ures S6E and S6F). The sole administration of NO inhibitors in
heavily engrafted leukemic mice did not produce any significant
decrease of leukemic load in the BM (Figure S6E), likely due to
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Figure 5. AML Engraftment Is Associated with
Increased Nitric Oxide Levels in the BM
(A) Nitric oxide levels shown as DAF fluorescence intensity
(normalized mean fluorescence intensity [MFI]) in BM cells of
non-transplanted mice (ctrl) and mice transplanted with CB-
derived HSPCs (CB) or AML patient-derived samples, as de-
picted. Ctrl, n = 13; CB, n = 24; AML patients (AML1, 2, 6, 8, 9),
n = 35. Data are shown as minimum-to-maximum box plots, the
line inside the box representing the mean.
(B) Nitric oxide levels (normalized MFI) in BM cells of mice
transplantedwith AML patient-derived cells, treatedwith solvent
or AraC, as depicted. AML patients: AML6 and 9. UT, n = 7;
AraC, n = 7. Data are shown as minimum-to-maximum box
plots, the line inside the box representing the mean.
(C) Nitric oxide levels in BM cells of healthy donors or AML pa-
tients at diagnosis. Healthy ctrl, n = 8; AML patients, n = 19. Error
bars represent mean ± SEM.
(D) Nitric oxide levels in BM cells of AML patients at diagnosis (D)
and post treatment (PT); n = 18. Error bars represent mean.
(E) Pie chart showing the percentage of patients with decreased
or stable/increased levels of nitric oxide after treatment.
(F) NOS3 expressionmeasured via flow cytometry in Nestin+ and
CD31+ cells, as depicted. Data are representative of triplicates.
(G) Percentage of NOS3+ ECsmeasured by flow cytometry in the
BM of non-transplanted mice and mice engrafted with CB-
derived HSPCs (CB) or AML patient-derived samples, as de-
picted. Ctrl, n = 8; CB, n = 12; AML patients (AML2, 6, 8, 9),
n = 24. Data are shown as mean ± SEM.
(H) Activated NOS3 (measured by flow cytometry with an anti-
phosphoSer1177 antibody) in CD31+ ECs of the BM of mice
engrafted with CB-derived CD34+ cells (CB) or AML patient-
derived samples, as depicted. CB, n = 4; AML patients (AML2,
6, 9), n = 9. Data are shown as mean ± SEM.
(I) Cellular ROS (left) and nitric oxide (right) levels in different
populations of BM-derived ECs, as depicted, in non-trans-
planted mice (ctrl). Data are representative of triplicates.
(J) Cellular ROS (left) and nitric oxide (right) levels in different
populations of BM-derived ECs, as depicted, in mice engrafted
with AML6 patient-derived cells. Data are representative of
triplicates.
ns, not significant; *p < 0.05, **p < 0.01, ****p < 0.0001. See also
Figure S5.
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the absence of a specific effect of NO on leukemic cells. Indeed,
treatment of leukemic cells (ML1 or primary patient samples)
in vitro with NO inhibitor or NO donor did not affect their survival
or proliferation ability (Figures S6G and S6H). NO inhibition com-
bined with AraC treatment reduced NOS3 activation (Figure 6D),
vascular leakiness (Figure S6I), and the BM hypoxia (Figure 6E).
Importantly, the combined treatment was more powerful than
the chemotherapy alone in reducing leukemic progression in
the BM (Figures 6F and S6J) and the spleen (Figure S6K) of
mice engrafted with two different patient-derived samples (Fig-
ure S6L). The combined treatment also significantly extended
the ‘‘remission-like’’ phase of the disease compared with
chemotherapy alone (Figure 6G). These data show that
increased NO levels contribute to the vascular leakiness in
AML-engrafted mice, and restoring normal vascular function in
the BM by NOS inhibition improves the therapeutic response
compared with standard chemotherapy.
NOS Inhibition Potentiates Normal HSPC Function
Increased levels of NO have been associated with increased
HSPC motility and egress from the BM, leading to a lower repo-
pulation capacity of the BM stem cell pool after injuries (Aicher
et al., 2003; Gur-Cohen et al., 2015). Moreover, recent findings
indicate that loss of vascular integrity promotes HSPC mobiliza-
tion and loss of the HSC pool in the BM (Itkin et al., 2016). We
thus speculated that increased NO and vascular leakiness in
AML could affect normal HSC. In the BM of AML xenografts,
the residual murine HSC displayed higher levels of ROS (Fig-
ure 7A) and were mobilized to the periphery, as shown by
increased SLAM+ cells in the blood of mice with AML xeno-
grafts compared with those without, as well as a reduced pro-
portion of HSC in the BM (Figures 7B and 7C). The absolute
number of SLAM+ cells in the BM was also decreased in mice
with AML xenografts and in mice transplanted with murine
MLL-ENL leukemic cells (Figures S7A and S7B). Therefore,
we tested whether normalization of the vascular niche with
NOS inhibitors would be beneficial for normal HSC function.
We observed that NOS inhibitors in combination with AraC
treatment were more efficient than chemotherapy alone in re-
establishing the normal number of SLAM+ cells in the BM of
PDX (Figure 7D). Not only the number but also the stem cell
function of these SLAM+ cells was increased, as shown by their
repopulation ability in secondary recipients (Figures S7C and
7E–7G). These data suggest that overproduction of NO by
altered vascular niche affects normal residual HSC in the BM
and that NOS inhibition may improve AML therapy by restoring
normal stem cell function. We next tested the effect of NOS in-
hibitors on HSPCs. Hence, we treated mice engrafted with
normal HSPCs with NOS inhibitors and analyzed the effect
on the stem cell pool (Figure 7H). Interestingly, we observed
reduced HSPC egress to the blood (Figure 7I), an effect specific
for this compartment as no significant difference was observed
on the egress of total hCD45+ cells into the blood (Figure S7D).
This was accompanied by a specific increase of HSPCs in the
BM (Figures 7J and S7E). This effect was not due to an increase
in proliferation of the stem pool, as shown by cell-cycle analysis
(Figure S7F), thus excluding a possible exhaustion of the
compartment. Indeed, NO inhibition not only increased the
number of HSPCs in the BM but also their stem cell function,
as shown by their increased repopulation ability in secondary
transplantation assays (Figure 7K). We next tested whether
NO inhibition would be beneficial for residual normal HSPC to
outcompete AML cells during the relapse process. To achieve
this, and mimic the competition between AML cells and normal
HSCs into the BM niche, we injected simultaneously normal
human CB-derived HSPCs and AML patient-derived cells intra-
venously into non-irradiated NBSGW mice (McIntosh et al.,
2015) and monitored the normal versus malignant engraftment
in the presence or absence of long-term NOS inhibitors (Fig-
ure 7L). Analysis of the BM engraftment at the end of the treat-
ment showed that NOS inhibition favored the normal over
leukemic engraftment in the BM (Figures 7M and 7N). Together,
these results suggest that the use of NO inhibitors will not only
reverse the vascular permeability observed during AML pro-
gression and thus improve chemotherapy efficiency, but will
also restore a normal stem cell vascular niche, likely protecting
normal residual HSCs and allowing them to outcompete the
leukemic cells.
Altogether, our results provide strong evidence for the
importance of the alteration of the vascular niche in AML pro-
gression and relapse, via increased NO production by ECs,
and call for clinical trials incorporating NOS inhibitors to target
the abnormal vascular niche and improve the treatment
response.
Figure 6. Targeting Vascular Permeability Cooperates with Chemotherapy to Improve AML Treatment
(A) Percentage of murine GFP+MLL-AF9 #1 or tomato+ MLL-ENL #2 AML cells in the BM of secondary mice of depicted genotypes, treated with solvent or AraC;
n = 3 or more replicates. Data are shown as mean ± SEM.
(B) Representative 3D reconstruction of calvarium BM of mice of depicted genotypes transplanted with murine MLL-AF9 #1 AML cells, treated with solvent or
AraC. Scale bars represent 30 mm.
(C) Schematic of the experiment. Mice engrafted with human AML patients’ samples were treated with AraC or solvent for 1 week, and with or without NOS
inhibitors for 2 weeks.
(D) Activated NOS3 protein (measured by flow cytometry with an anti-phosphoSer1177 antibody) in CD31+ endothelial cells of the BM of mice transplanted with
AML6 and AML9 patient-derived cells, treated as described in (C); n = 6. Data are shown as mean ± SEM.
(E) Hypoxia represented as HypoxiSense signal intensity/voxel in the calvaria BM of non-transplanted mice (ctrl) and mice transplanted with AML6 patient-
derived samples, treated or not with AraC, as depicted. Ctrl UT, n = 13; ctrl AraC, n = 10; AML6 UT, n = 18; AML6 AraC, n = 20; AML6 A + N, n = 9; AML6 A + C,
n = 9. Data are shown as whiskers minimum-to-maximum plots, the line inside the box representing the mean, the top and the bottom lines representing the 75%
and 25% percentiles, respectively, and the lines above and below the box representing the SD.
(F) Percentage of human CD45+ engraftment in the BM of mice engrafted with patient-derived sample AML6 and treated as in (C); n = 3 per condition. Data are
shown as mean ± SEM.
(G) Percentage of human CD45+ engraftment measured via BM aspirate in mice engrafted with AML 6 and treated as in (C). Data are shown as mean ± SEM.
ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S6.
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DISCUSSION
Tumor angiogenesis is a pathological complication of several
types of solid cancers, which has been extensively studied and
characterized. The angiogenic process is mostly initiated by
pro-angiogenic factors derived from tumor cells, which in turn
activates a pro-inflammatory response in the microenvironment,
associated with the initiation of irregular and uncontrolled
vascular growth. Newly formed tumor vessels appear abnormal
and leaky in most of the solid cancers. This structurally aberrant
network affects the local blood flow, metabolite exchange, and
oxygenation, leading to poor drug delivery, increased tumor
growth, and metastatic potential (Carmeliet and Jain, 2011a,
2011b; Jain, 2005).
In the AML context, leukemic cells have been shown to modify
ECs ex vivo via several pathways, mainly mediated by pro-angio-
genic factors such as VEGF family members (Kampen et al.,
2013; Poulos et al., 2014). Moreover, publicly available datasets
as well as several studies reported that VEGF is not the only pro-
angiogenic factor produced by AML cells, which may be a major
reason why clinical trials incorporating VEGF inhibitors have not
been very successful. AML cells also express high levels of he-
patocyte growth factor (Aref et al., 2002), fibroblast growth factor
(Ribatti et al., 2007), and other factors (Chand et al., 2016; Hat-
field et al., 2009; Lee and Kim, 2014). However, no extensive
analysis of the AML vascular niche in vivo has been reported.
In the present study, we provide a detailed picture of the
vasculature in AML. We not only confirm that AML engraftment
induces hypoxia and angiogenesis in the BM but also show
that it alters the normal vascular architecture and function. ECs
involved in the angiogenic process are highly metabolically
active and consume a high level of oxygen (Potente and Carme-
liet, 2017). As a result, these newly formed abnormal vessels are
incapable of supplying nutrients and oxygen (as well as drugs) in
a homogeneous way in the BM tissue, likely contributing tomain-
tain the overall hypoxia. At a late stage of disease, after facing an
exponential and uncontrolled growth and being exposed to high
levels of NO/ROS production, ECs display an increased
apoptotic phenotype, likely associated with a toxic process of
vascular regression (Lobov et al., 2011).
The crosstalk between leukemic cells and ECs in the BM has
not been extensively studied at themolecular level. The available
data in the literature rely on the in vitro co-culture system, which
does not faithfully reproduce the complexity of the in vivo envi-
ronment. Our analysis of the transcriptome of vascular ECs
upon human AML engraftment provides important insights into
the field. First, it confirms at the molecular level the observed
toxic phenotypes. Second, it highlights commonly deregulated
genes and pathways, which can represent potential targets for
the disruption of the AML-microenvironment crosstalk. Interest-
ingly, the NOX4-NOS3 axis, already reported previously to act in
response to stress induced by hypoxic conditions (Craige et al.,
2011; Drummond et al., 2000; Mittal et al., 2007; Thomas et al.,
2002; Zhang et al., 2008), has a major role in orchestrating the
AML-induced vascular leakiness.
Persistent vascular leakiness and increased NO levels in AML
xenografts after induction therapy suggest that the abnormal
and poorly functional vessels participate to maintain a hypoxic
vascular environment during the remission phase, likely contrib-
uting to treatment failure. Our hypothesis is strengthened by the
analysis of NO in an independent cohort of patients which,
although relatively small, faithfully represents the high diversity
of the AML genetic landscape. Our analysis argues for NO as a
potential prognostic BM marker, as stable/increased levels of
NO post-induction therapy seems to be associated with a poor
clinical outcome.
Increased vascular leakiness can lead to poor drug delivery
and to a microenvironment favoring resistance to therapy and
Figure 7. Targeting Vascular Permeability Potentiates HSPC Function
(A) Cellular ROS levels in BM-derived HSC of non-transplanted mice or mice engrafted with AML6 patient-derived cells. Data are representative of triplicates.
(B) Percentage of murine HSC among total murine CD45+ cells in the blood of non-transplanted mice and mice engrafted with AML6 patient-derived cells. ctrl,
n = 5; AML6, n = 3. Data are shown as mean ± SEM.
(C) Percentage of murine HSC among total murine CD45+ cells in the BM of non-transplanted mice of mice engrafted with AML patient-derived samples
(AML6, 9). ctrl, n = 5; AML patients, n = 12. Data are shown as mean ± SEM.
(D) Absolute number of murine HSC in the BM of mice transplanted with AML patient-derived cells, as depicted, and treated with AraC alone or in combination
with NOS inhibitors. Each dot represents a mouse. Error bars represent mean.
(E–G) Percentage in blood (E) and absolute number in BM (F) and spleen (G) of donor CD45.1, retrieved from NSG mice transplanted with AML6 patient-derived
cells and treated with AraC alone or in combination with NOS inhibitors, injected in secondary CD45.2 Rag2-KO/Gammac-KO mice. AraC, n = 4; A + N, n = 3;
A + C, n = 3. Data are shown as mean ± SEM.
(H) Schematic of the experiment. Mice engrafted with human CD34+ CB cells were treated with NOS inhibitors (NG-monomethyl-L-arginine [NMMA]
20 mg/kg/day intraperitoneally or cavtratin 2 mg/kg/day intraperitoneally) for 2 weeks, 5 days/week. Mice were euthanized and BMC harvested for subsequent
analysis and secondary transplantation.
(I) Percentage of HSPCs in the peripheral blood of mice engrafted with CB-derived HSPCs and treated or not with NMMA or cavtratin. Data are shown as
mean ± SEM.
(J) Absolute number of HSPC in the BM of mice engrafted with CB-derived HSPC cells and treated or not with NMMA or cavtratin. Data are shown as
mean ± SEM.
(K) Absolute number of human CD45+ cells in the BM (left) and spleen (right) of secondary NSG mice transplanted with primary xenografts described in (H). Data
are shown as mean ± SEM.
(L) Schematic of the experiment. Non-irradiated NBSGW mice were simultaneously transplanted with tomato+ HSPCs (red) and non-transduced AML6 (black)
patient-derived cells, and 2 weeks after transplantation control solvent or NMMAwere administered for 6 weeks, 5 days/week. Two days after the last treatment,
mice were euthanized and BM was analyzed.
(M) Percentage of tomato+ (normal, red) and tomato (leukemic, black) cells among hCD45+ in the BM of mice described in (L); n = 4. Data are shown as
mean ± SEM.
(N) Absolute number of tomato+ hCD45+ (normal) cells in the BM of mice described in (L). Data are shown as mean ± SEM.
ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S7.
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relapse. Theparticipation of vascular leakiness to thepathophys-
iology of AML can be exerted at different levels. First, increased
vascular permeability deregulates the balance of blood supply
to the BM and, consequently, drug delivery. This leads to the for-
mation of areas with low perfusion rate, where leukemic cells can
hide and escape therapy. Restoring a normal vascular function
would allow more homogeneous chemotherapeutic delivery.
Second, high vascular permeability (Itkin et al., 2016) and high
NO levels (Gur-Cohen et al., 2015) have recently been associated
with increased HSC activation and egress from the BM in mice,
with a consequent reduction of their repopulating activity. Our
data showing increased ROS levels and higher egress of BM-
derived HSCs are in line with these findings, further extending
them to the humanHSPCcompartment. Indeed,we show that in-
hibition of NO results in an enriched number and activity of BM
HSPCs. Conversely, the presence of AML engraftment induces
the generation of an exogenous overproduction of NO in the
BM, which likely affects the HSC motility and activity, bringing a
rapid exhaustion of their functionality. In this scenario, inhibition
of NO would produce multiple benefits to AML patients. NOS in-
hibitors are already in clinical trials (Granados-Principal et al.,
2015; Ozkor et al., 2015) and specific inhibitors of NOS3 have
been developed (Bucci et al., 2000; Gratton et al., 2003). Thus,
our preclinical data using both genetic and pharmacologic ap-
proaches to inhibit NO in combination with AraC treatment
show that targeting vascular permeability would be a successful
strategy to normalize theBMvascular functionality, improve ther-
apeutic responses, and preserve normal HSC function.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD45 30-F11 1 in 400 Mouse eBioscience Cat: 45-0451-82;
RRID: AB_1107002
TER119 Ter-119 1 in 400 Mouse eBioscience Cat:12-5921-82;
RRID: AB_466042
CD31 390 1 in 400 Mouse eBioscience Cat: 25-0311-82; RRID: AB_469616
Endomucin V.7C7 1 in 100 Mouse Santa Cruz Biotechnology Cat: sc-65495; RRID: AB_2100037)
Sca-1 D7 1 in 400 Mouse eBioscience Cat: 17-5981-83
RRID: AB_469488
Lin - 1 in 400 Mouse Biolegend Cat: 133311; RRID: AB_11203535
Kit 2B8 1 in 400 Mouse BD Bioscience Cat: 553354; RRID: AB_394805
CD48 HM48-1 1 in 400 Mouse Biolegend Cat: 103432; RRID: AB_256163
CD150 TC15-12F12.2 1 in 400 Mouse Biolegend Cat: 115914; RRID: AB_439797
IB4 - 100ug/mouse Mouse Life Technology Cat: I21411; RRID: AB_2314662
Sca-1/Ly6A/E EPR3355 1 in 100 Mouse Abcam Cat: ab109211; RRID: AB_10862573
Ki67 SolA15 2 in 100 Mouse eBioscience Cat: 12-5698-82; RRID: AB_11150954
Ki67 20Raj1 2 in 100 Human eBioscience Cat: 50-5699-82; RRID: AB_2574237
rAnnexin V - 2 in 100 Mouse/Human eBioscience Cat: BMS306; RRID: AB_2687874
CD45 PD7/26 + 2B11 1 in 100 Human Dako Cat: M0701; RRID: AB_2314143
CD34 581 1 in 25 Human BD Bioscience Cat: 555821; RRID: AB_396150
CD45 2D1 1 in 25 Human BD Bioscience Cat: 47-0459-42; RRID: AB_1944368
CD38 HIT2 1 in 25 Human BD Bioscience Cat: 555462; RRID: AB_1994368
Ki67 20Raj1 1 in 25 Human eBioscience Cat: 50-5699; RRID: AB_2574237
CD45 HI30 20ug/mouse Human Biolegend Cat: 304017; RRID: AB_389314
NOS3-pSER1177 C9C3 1 in 100
Mouse/Human
Cell Signaling Cat: 9570S; RRID: AB_823493
NOS3 33/eNOS 1 in 20 Mouse/Human BD Bioscience Cat: 560103; RRID: AB_1645506
NOS2 CXNFT 1 in 100 Mouse/Human eBioscience Cat: 17-5920-80; RRID: AB_2573243
Bacterial and Virus Strains
pHAGE2-EF1aFull-MCS-IRES-Tomato Kind gift of G. Mostoslavsky; modified
from J Immunol Methods. 2008;329:31–44
N/A
pTWG-CMV-LUC-eGFP Modified from pTWG-eGFP (Addgene)
and N/A pGL4-50 luciferase reporter
(Promega)
N/A
Biological Samples
See Tables 1, S1, and S2 N/A N/A
Chemicals, Peptides, and Recombinant Proteins
Hypoxyprobe Plus Kit Natural Pharmacia International HP2-1000Kit
HypoxiSense 680 Fluorescent
Imaging Agent
PerkinElmer NEV11070
DAF-FM DA solution Sigma-Aldrich D2321
CellROX Deep Red Reagent Thermo Fisher Scientific C10422
NG-Methyl-L-arginine acetate salt (NMMA) Sigma-Aldrich M7033
Caveolin-1 scaffolding domain peptide
(Cavtratin)
Enzolifesciences ALX-153-064-M005
S-Nitroso-N-acetyl-DL-penicillamine (SNAP) Sigma-Aldrich N3398
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to the Lead Contact Dominique Bonnet at
dominique.bonnet@crick.ac.uk
Human Primary Samples
Umbilical Cord Blood (CB) samples were obtained from normal full-term deliveries after signed informed consent. AML samples used
for xenografts were obtained after informed consent at St Bartholomew’s Hospital (London, UK). Details are listed in Table 1. BM
specimens from 19 adult patients with newly diagnosed, untreated AML were also obtained after informed consent at St Bartholo-
mew’s Hospital (London, UK). Patient characteristics are depicted in Table S1. Additional BM biopsies were available from these
same 19 patients following chemotherapy (details in Table S2). To establish controls, BM biopsies were obtained either from healthy
donors for bone marrow transplantation or from patients with diffuse large cell lymphoma without BM infiltration (Table S2). The
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
RNA-sequencing data in CD31+
BM-derived endothelial cells
GSE88905 http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE88905
Experimental Models: Cell Lines
HL60 ATCC Cell Service, The Francis Crick Institute
ML1 ATCC Cell Service, The Francis Crick Institute
U937 ATCC Cell Service, The Francis Crick Institute
Experimental Models: Organisms/Strains
NOD-SCID IL2Rgnull (NSG) Jackson Laboratory 005557
NSG-NESTIN-GFP The original strain is a kind gift from
Dr G. Enikolopov. Back-crossed to NSG
background at the BRF, The Francis
Crick Institute (generation 8)
N/A
NSG-NG2-DSRED Original strain from Jackson Laboratory
(008241). Back-crossed to NSG
background at the BRF, The Francis
Crick Institute (generation 8)
N/A
C57BL/6 Jackson Laboratory 000664
C57BL/6 Nos3-KO Jackson Laboratory 002684
NSG- KitW41/W41 (NBSGW) Jackson Laboratory 026622
C57BL/6-Rag2-KO-GammaC-KO BRF, The Francis Crick Institute N/A
Oligonucleotides
Human VEGFA REV Sigma-Aldrich 5’-TGGCCTTGGTGAGGTTTGATCC-3’
Human NOS2 FW Sigma-Aldrich 5’-GGTGCTGTATTTCCTTACGAGGCG-3’
Human NOS2 REV Sigma-Aldrich 5’-CTTGTTAGGAGGTCAAGTAAAGGGC-3’
Human NOS3 FW Sigma-Aldrich 5’-CGGCATCACCAGGAAGAAGA-3’
Human NOS3 REV Sigma-Aldrich 5’-CATGAGCGAGGCGGAGAT-3’
Human GAPDH FW Sigma-Aldrich 5’-GGGAAGGTGAAGGTCGGAG-3’
Human GAPDH REV Sigma-Aldrich 5’-GGGTCATTGATGGCAACAA-3’
Murine NOS3 FW Sigma-Aldrich 5’-CCTTCCGCTACCAGCCAGA-3’
Murine NOS3 REV Sigma-Aldrich 5’-CAGAGATCTTCACTGCATTGGCTA-3’
Murine NOX4 FW Sigma-Aldrich 5’-ACTTTTCATTGGGCGTCCTC-3’
Murine NOX4 REV Sigma-Aldrich 5’-AGAACTGGGTCCACAGCAGA-3’
Murine GAPDH FW Sigma-Aldrich 5’-AACTTTGGCATTGTGGAAGG-3’
Murine GAPDH REV Sigma-Aldrich 5’-CACATTGGGGGTAGGAACA-3’
Software and Algorithms
ZEN microscope software Zeiss N/A
IMARIS 8.3.1 image analysis software Bitplane N/A
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collection and use of all human samples were approved by the East London Research Ethical Committee (REC:06/Q0604/110) and in
accordance with the Declaration of Helsinki. Mononuclear cells (MNCs) were isolated by centrifugation using Ficoll-Paque TM PLUS
(GE Healthcare Life Sciences, Buckinghamshire, UK). For CB samples, the cells were processed within 24 hours following collection.
Cells were enriched for CD34+, using an EasySep Human CD34 Positive Selection kit (StemCell Technologies, Vancouver, Canada)
according to the manufacturer’s instructions, with a purity of 85 to 99%. T cells were depleted from all AML samples using the anti-
CD3 mAb OKT-3 (West Lebanon, USA).
Mouse Models
All animal experiments were performed under the project license (PPL 70/8904) approved by the Home Office of UK and in accor-
dance to The Francis Crick institute animal ethics committee guidelines. NESTIN-GFP mice were a kind gift from Dr G. Enikolopov.
NOD-SCID IL2Rgnull (NSG), C57BL/6, NG2-DSRED, Nos3-KO, Rag2-KO/GammaC-KO and NOD.B6-SCID c-KitW41/W41 (NBSGW)
strains were obtained from Jackson Laboratory, Bar Harbor, Maine, USA) and were bred at The Francis Crick Institute Biological
Resources Facility in individually vented cages (IVCs) under Specific Pathogen Free (SPF) conditions. NSG-NESTIN-GFP and
NSG-NG2-DSRED mice were obtained by back-crossing the original lines into the NSG background (generation 8 or more).
Drug Treatments In Vivo
AraC was administrated subcutaneously at the indicated doses (10 mg/kg/day for NSGmice and 60 mg/kg/day for C57BL6 mice) at
specific time points, for 7 days, as depicted. To inhibit NOS activity, mice received intraperitoneal injection of NMMA (20 mg/kg/day;
Sigma-Aldrich, Gillingham, Dorset, UK) or Cavtratin (2.5 mg/kg/day, Enzo LifeScience), or vehicle, for 2 weeks, 5 days/week. All
animal work was in accordance to the Home Office and The Francis Crick guidelines.
Intravital Two-Photon Microscopy
For intravital imaging in time-lapse, mice were anesthetized with 2.5% Isoflurane, the head shaved and held in a stereotaxic skull
holder. A skin incision revealed the calvaria and methylcellulose (4%, Sigma-Aldrich, Gillingham, Dorset, UK) was applied to prevent
the tissue drying. For imaging at a single time point, mice were euthanized by cervical dislocation, the skin was removed, and the
intact skull was immerged in PBS for direct examination of the calvarium under the microscope. Images were obtained on a Zeiss
710 NLO laser scanning multiphoton microscope with a 20x 1.0 NA water immersion lens. The microscope was equipped with a
MaiTai ‘‘High Performance’’ fully automated 1-box 517 mode-locked Ti:Sapphire laser with DeepSee dispersion compensation
(Spectra-Physics), tuned to 890 nm excitation wavelength. To assess the hypoxia with hypoxisense probe, mice received an i.v.
injection of 0.4 mg of human normal immunoglobulin twice (48 and 24 hours prior to imaging) (Gammaplex, Bio Products Laboratory,
Hertfordshire, UK). The HypoxySense 680 probe (ref: NEV11070, PerkinElmer, Massachusetts, US) was injected 24 hours prior im-
aging (according to the manufacturer instructions), and on the day of imaging each mouse was intravenously injected with 100 ml of
human CD45 AF488 antibody (Biolegend, Cat:304017) 30 minutes prior sacrifice, or with 150 kDa TRITC-dextran in case of NSG-
Nestin-GFP mice. Mice were imaged as described above. Bone signal (Second Harmonic Generation, SHG) was collected at
380-485nm, hCD45 or Nestin-GFP at 500-550nm, TRITC-dextran at 555-625nm and Hypoxisense at 640-690nm with a 750 nm Infra
Red filter by not descanned detectors. To assess vascular perfusion, 100 ug of IB4-AF488 (Life Technology, Cat: I21411) were i.v.
injected into mice 30 min prior imaging. 15 ml of Qtracker 655 Vascular Labels (Thermo Fisher Scientific, Cat: Q21021MP) were
injected i.v. 1 min prior imaging. SHG was collected at 380-485nm, IB4-AF488 at 500-550nm, and Qtracker at 640-690nm by not
descanned detectors. To assess the hypoxic state of the vasculature, NSG-Nestin-GFP mice were used, and TRITC-dextran
(150 kDa) was intravenously injected 1 min before imaging to label the vascular tree. SHG was collected at 380-485nm, Nestin-
GFP at 500-550nm, TRITC dextran at 555-625nm and Hypoxisense at 640-690nm with a 750 nm Infra Red filter by not descanned
detectors. To image the vascular leakiness, we used the strategy detailed in Figure S2E. Briefly, two vessel-pooling agents of
different molecular weights were intravenously injected simultaneously: Qtracker 655 Vascular Labels (Thermo Fisher Scientific,
Cat: Q21021MP), high molecular weight and 65-85 kDa TRITRC dextran, medium molecular weight (Sigma-Aldrich, Gillingham,
Dorset, UK). Mice were imaged at different time points (Figure 2C) after probes injection, or 10 min after probes administration in
all other cases. Calvarium was imaged. SHG was collected at 380-485nm, GFP, 65-85 kDa TRITC dextran at 555-625nm, and
655- Qtracker at 640-690nm by not descanned detectors. Each z stack of images (100-150 mM) was rendered in 3D using Imaris
software (Bitplane). At least 9 images representing different areas of bone were taken per group.
Images Processing
Tomeasure vessel mean diameter, the ‘filament’’ algorithmwas applied using the signal intensity derived from the NT-Qdot in the BM
vasculature (Imaris, Bitplane). Tomeasure the distance to hypoxic areas of BM vessels, a volumetric iso-surfacewas generated using
the signal intensity derived from the Hypoxisense. A map of distances from the Hypoxisense iso-surface was calculated with
‘‘Distance Transformation’’ tool using Imaris XT extension. A volumetric iso-surface to define the vessels was then generated using
the intensity derived from the dextran. The distance between each vessel and the closest hypoxiprobe pixel wasmeasured (Bitplane).
To assess the vascular leakiness, the signal intensity derived from the Qtracker was used to generate a volumetric iso-surface of the
BM vasculature, using the standard surface algoritm of IMARIS. ‘‘Background Subtraction’’ (5-10% based on local contrast) was
performed with manual threshold. The iso-surface was then used to segment the signal intensity (SUM) derived from the dextran
in ‘‘IN’’ and ‘‘OUT’’ the vasculature, using the ‘‘Mask Settings’’ function. The ratio between these two intensities (OUT/IN) represents
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the leakiness of the vasculature at a given time point (Imaris, Bitplane). To measure the distance of AML cells to vessels, a volumetric
iso-surface was generated using the signal intensity derived from the dextran. A map of distances from the Hypoxisense iso-surface
was calculated with ‘‘Distance Transformation’’ tool using Imaris XT extension. The spot function was used to identify hCD45+ cells.
The distance between each spot and the closest vascular pixel wasmeasured (Bitplane). To quantify the hypoxia, in each z-stack the
hypoxisense signal intensity and the total volume of the z-stack (voxel) were calculated. The hypoxia was expressed as signal inten-
sity/voxel (Imaris, Bitplane).
Bioluminescence Imaging
Before imaging, each mouse was given an intraperitoneal injection of 125 mg/kg luciferin (Caliper Life Science). General anesthesia
was induced with 2% isoflurane and the mouse was placed in a light-tight heated chamber. After acquiring bright-field images of
each mouse, anterior and posterior luminescent images were then successively acquired with 1- to 5-min exposure time. Optical
images were displayed and analyzed with the IVIS Living Image software (Caliper Life Science). Regions of interest were manually
drawn around the bodies of the mice to assess the intensity of the bioluminescence signal for each mouse. Optical signal was ex-
pressed as photon count.
Cell Lines
293 HEK were grown in DMEM; HL60, ML1 and U937 were grown in RPMI1640, MS5 in IMDM. All cell lines were tested for myco-
plasma prior to commencing experiments. All cell lines came originally ATCC (distributor LGC standards, UK) and were grown by our
cell service at the Institute. Before use these lines, they were authenticated using the Short Tandem Repeat (SRF) profiling. All media
were supplemented with 10% FBS and 1x Penicillin-Streptomycin and all reagents were from Gibco-Life Technologies
(Paisley, UK).
Transduction and Culture of Human Primary Samples
T-cell depleted hAML MNCs were pre-stimulated in StemSpam SFEM (StemCell Technologies, Vancouver, Canada) supplemented
with 25 ng/ml G-CSF or 100ng/ml SCF, 100ng/ml Flt3-L, 60ng/ml IL-3 and 10ng/ml TPO (PrepoTech, London, UK), respectively for 4
to 6 hours. CD34-enriched HSPCs were pre-stimulated in StemSpam SFEM (StemCell Technologies, Vancouver, Canada) supple-
mented with 25 ng/ml G-CSF, 150ng/ml SCF, 150ng/ml Flt3-L, 10ng/ml IL-6 and 20ng/ml TPO (PrepoTech, London, UK) for 4 to
6 hours. Lentiviral supernatant (GFP-Luciferase vector for human AML MNCs and tomato vector (Pan et al., 2008) for HSPCs)
was added at a multiplicity of infection (MOI) of 30 in the presence of 5mg/mL polybrene for 12 hours. The cells were then washed
and expanded in culture. The efficiency of transduction was analyzed after 4 days by GFP expression. Primary hAML cells were
co-cultured on a layer of primary humanMSC for one week. Transduced AML cells were co-cultured on MS-5 cells for 4 days before
sorting on the human CD45 and GFP fraction and injected into mice. Cells were grown in Myelocult H5100 medium (StemCell Tech-
nologies, Vancouver) supplemented with 20ng/ml IL-3, 20ng/ml G-CSF and 20ng/ml TPO (PeproTech, London, UK). Transduced
HSPC cells were grown in StemSpam SFEM supplementer with 150 ng/ml SCF, 150 ng/ml Flt-3 and 20 ng/ml TPO for 4 days before
sorting on the human CD45 and tomato fraction and injected into mice.
Transduction and Culture of Murine Primary Samples
Primary murine AML carrying the MLL-AF9 or MLL-ENL translocations were generated as reported (Horton et al., 2009). Leukemic
cells retrieved from BM or spleen of primary leukemic mice (MLL-AF9 #1, MLL-ENL #1 and #2) were cultured in RPMI supplemented
with 10% FCS, 10 ng/ml IL3, 10 ng/ml IL6, 100 ng/ml SCF (Sigma-Aldrich, Gillingham, Dorset, UK). Cells were infected by spinocu-
lation with a lentivirus expressing GFP-Luciferase (MLL-AF9 #1 and MLL-ENL #1) or tomato (MLL-ENL #2) (centrifugation at 700g,
25C, 45 minutes) in the presence of 5mg/mL polybrene (Sigma-Aldrich, Gillingham, Dorset, UK), as previously described (Horton
et al., 2005).
AML and HSPCs Transplantation Assay In Vivo
Murine AML
Murine AML cells from culture were transplanted into sub-lethally irradiated C57BL6mice. Secondary AML cells retrieved from these
animals were transplanted into unconditioned WT or Nos3-KO mice at the indicated concentrations.
Murine Normal HSC
For HSC in vivo functionality assays, murine CD45.1 cells retrieved from NSG mice were isolated using an EasySep murine CD45
Positive Selection kit (StemCell Technologies, Vancouver, Canada) and 250000 cells were transplanted i.v. into sub-lethally irradiated
Rag2-KO/GammaC-KO secondary recipients.
Xenografts
For xenografts assays, human AML cell lines, AML patient-derived samples and HSPC were transplanted into 8- to 12-week old un-
conditioned NSG or NSG-NESTIN-GFP and NSG-NG2-DSRED mice by i.v. injection, as indicated. For competitive transplantation
experiments, 5,000 tomato+ HSPCs were injected together with 100000 untransduced AML6 cells i.v. into unconditioned NBSGW
mice (Jackson Laboratory, BarHarbor, Maine, USA). BM engraftment was assessed by BM aspirate or bioluminescence, when
indicated.
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Bone Marrow Cell Isolation
At the end of each experiment, animals were euthanized by cervical dislocation and the 6 rear bones collected in cold PBS. To
retrieve BM endothelial and mesenchymal cells, bones were dissected in small pieces of 2-3 mm diameter and incubated 30 min
at 37 degrees in a HBSS digestion solution containing 2% FBS, DNase I (10 mg/ml), Collagenase (1 mg/ml), Dispase II (5 mg/ml)
and Heparin (20 U/ml), all from Sigma-Aldrich, Gillingham, Dorset, UK. Bone pieces were next crashed with mortar and pestle in
the same digestion solution and incubated at 37 degrees for 30 min. Cell suspension was then homogenized with a micropipette
and filtered with a 100 micron cell strainer.
HO Diffusion
Mice were administrated with two injections of 0.4 mg HO (Sigma-Aldrich, Gillingham, Dorset, UK) at 5 minutes interval, and eutha-
nized 5minutes later. After cervical dislocation, bones were quickly dissected and immediately immersed in ice-cold PBS containing
inhibitors of the APC-efflux pump (Reserpine, Verapamil; Sigma-Aldrich, Gillingham, Dorset, UK) to avoid HO extrusion. Cells were
recovered and processed as described above and stainedwith specific surface antibodies. HO uptakewas calculated by dividing the
geometric mean fluorescence intensity of the HO blue channel by the same analysis carried out on the same population of cells from
the same organ but from an animal not injected with HO (negative control). This corresponds to the specific fluorescence intensity
and reflects the actual uptake of HO by the population of interest.
Hypoxiprobe Assessment
Pimonidazole (PIM; Hypoxyprobe) was purchased from Natural Pharmacia International, Inc. Mice were i.v. injected with 125 mg/kg
PIM or saline solution and euthanized after 2 hours. For flow cytometry analysis, bones were rapidly harvested and kept in PBS at
4C. Cells were recovered and processed as described above, and stainedwith specific surface antibodies. Next, they were permea-
bilized (BD Cytofix/Cytoperm kit) and stained with specific FITC-MAb1, following manufacturer instructions. Cells from PIM non-in-
jected animals but stained with the same concentration of relevant antibody after permeabilization were used as a negative control to
calculate the specific geometric mean fluorescence intensity as previously reported (Lassailly et al., 2013). For IHC analysis, samples
were processed as described below, and stained with primary FITC-MAb1 and secondary anti-FITC-HRP following manufacturer
instructions.
Flow Cytometry Analysis and Cell Sorting
Flow cytometry analysis was performed using a Fortessa flow cytometer (BD Biosciences, Oxford, UK). AML transduced cells were
identified based on their GFP expression. Dead cells and debris were excluded from the analysis using 4,6, diamidino-2-phenylindole
(DAPI) staining. Murine HSC (SLAM) were defined by the expression of these surfacemarkers: CD45+LIN-Kit+CD48-CD150+, with the
exclusion of Tomato+ murine AML cells or hCD45+ human AML cells. DAF-FM probe was used to measure intracellular NO, using
manufacturer instructions (D2321, Sigma-Aldrich, Gillingham, Dorset, UK). In particular, bonemarrow cells were incubated for 30min
at 37 degrees with the probe at 5 uM, and extensively washed afterwards before analysis. CellROX Deep Red Reagent was used to
measure cellular ROS, following manufacturer instructions (C10422 – ThermoFisher Scientific). For intracellular staining, cells were
fixed and permeabilized after surface epitope staining using BD Cytofix/Cytoperm kit, following manufacturer instruction (BD Biosci-
ence, Oxford, UK). Cell sorting was performed using a FACS Aria SORP (BD Biosciences, Oxford, UK). Human AML cell lines and
primary patient-derived AML cells were sorted according to the expression of GFP and hCD45.Murine endothelial andmesenchymal
cells were analyzed and sorted based on the absence of expression of CD45 and Ter119 makers, and the positive expression of
CD31 and Nestin-GFP, respectively. Flow cytometry plots displayed in this manuscript represent one set of data points from at least
3 replicates. Antibodies informations are included in the Key Resources Table.
Drug Treatments In Vitro
Human ML1 cells were seeded alone or on a confluent layer of MS-5 cells for 24 hours before starting the treatments. NMMA was
used at a concentration of 5mM for 48 hours before assessing apoptosis. Primary AML-derived samples were seeded on a confluent
layer of MS-5 cells for 4 days before starting the treatment. Drugs were added to the culture (NMMA at 5 mM and SNAP at 10 mm;
Sigma-Aldrich, Gillingham, Dorset, UK) for 5 days before assessing apoptosis and cell cycle.
Reverse Transcriptase and Real Time Quantitative PCR (RT-qPCR)
Total RNA from sorted cell samples was isolated using the RNeasy Mini Kit (Qiagen, Crawley, UK) according to the manufacturer’s
instructions. mRNA was reverse transcribed by Superscript III Reverse Transcriptase (Invitrogen) with an oligoDT primer (Sigma-
Aldrich, Gillingham, Dorset, UK). RT-qPCR was performed with an ABI 7500 FAST Thermal Cycler (Applied Biosystems) using
SYBR Green dye (Applied Biosystems). RNA was quantified with the Comparative CT Method and GAPDH was used as a house-
keeping gene. The CT values used were the result of triplicates. The primers used are described in the Key Resources Table.
Histological Processing and Immunostaining
Murine samples. Harvested humerus samples were fixed o/n in 10% neutral buffered formalin and then decalcified with 17% EDTA
(Osteosoft, Millipore) during 7 days. Samples were processed, paraffin embedded and sectioned (5 mm) for histological studies.
Hematoxylin/eosin was performed first to assess quality of the sections of BM samples and visualize vessel integrity. For
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immunofluorescence (IF) studies heat antigen retrieval was performed in all cases. Primary antibodies are listed in the key resources
table. Goat anti-mouse/rabbit/rat secondaries antibodies coupled to AF-488, AF555 and AF647 were used (all from Invitrogen). DAPI
was included in the mounting media to label the nuclei. Images were obtained with a Zeiss LSM710 upright confocal microscope. At
least 3 images were taken per sample group. To quantify micro-vascular density (MVD), the number of vessel sprouts/mm2 was
counted (Bitplane), and data are show as fold over ctrl.
Sample Preparation for RNA-Sequencing
The quality and concentration of total RNA were determined on Agilent 2100 Bioanalyzer using the Eukaryote Total RNA Pico Assay.
Most of the total RNA has average RIN number 5-8, with a concentration at least 4 pg/ml. Some of the samples were concentrated on
a speedvac without heat to obtain a final volume of 5 ml. 3.5 ng of Total RNA in 5 ml volumewas used to generate cDNA synthesis with
NugenOvationRNA-Seq SystemV2 kit (part No. 7102). The resulting SPIA-cDNAwere normalized to 100 ng in 15 ml based onQubit
DNA HS assay. Fragmentation was done using 8microTUBE-15 AFA Beads Strip V2 (PN 520159) on Covaris E-series at setting 20%
DF, 18W, 200 burst, 20C tempt, 120s treatment time and no Intensifier. Only 10-30 ng in 10 ml of fragmented cDNA was used starting
from the End Repair step of the Ovation Ultralow Library Systems V2 (part No. 0344NB) protocol, with 10 cycles PCR. The RNAseq
libraries were quality checked onQubit DNAHSassay, Bioanalyser and Illumina Ecoreal QPCR followed by Illumina PE51 sequencing
on Hiseq 2500 V3 reagents.
RNA-Sequencing Analysis Methods
FastQ files were generated using CASAVA BCL to FastQ (version 2.16). Sequencing yield was typically 25 million strand-specific
paired-end reads. The RSEM package (version 1.2.29) (Li and Dewey, 2011) in conjunction with the STAR alignment algorithm
(version 2.5.1b) (Dobin et al., 2013) was used for the mapping and subsequent gene-level counting of the sequenced reads with
respect to mm10 Ensembl genes downloaded from the UCSC Table Browser 15 on 14th April 2016 (Karolchik et al., 2004). The ‘‘–for-
ward-prob’’ parameter was set to ‘‘0’’ and all other parameters were kept as default. Differential expression analysis was performed
with the DESeq2 package (version 1.10.1) (Love et al., 2014) within the R programming environment (version 3.2.3) (R Development
Core Team, 2015). Genes with FDR <0.05 were judged to be differentially expressed. Genes from each given pairwise comparison
were ranked using the Wald statistic. GSEA pre-ranked analysis was performed with respect to MSigDB (version 5.1) (Subramanian
et al., 2005) genesets C2 canonical pathways and C5 GO biological process. All parameters were kept as default except for enrich-
ment statistic (weighted), min size (5) and max size (50000).
Statistical Analysis
Statistics were performed with Prism (GraphPad). Unpaired Student’s t-test was used to compare two groups, except in Figure 5E
and S3B and S5B, where paired Student’s t-test was used. Log-rank test was used for survival curves. Details of each analysis are in
figure legends. For probabilities distribution in our cohort of patients, we have considered the joint probability distribution of twoBool-
ean variables: NO normalization and response to therapy. We applied Bayesian inference to estimate the probabilities of each of the
four possible combinations of these variables from the cohort of patients. These probabilities are related to the occurrence of each
combination of NO normalization and response to therapy, according to a multinomial distribution parameterized by the four prob-
abilities. We estimated these parameters from their posterior distributions obtained by updating a uniform prior using the data
available. The posterior distributions for the four probabilities have been obtained by generating a sample of the parameters of
the multinomial (N=1 106), weighted according to importance sampling. The generated sample was then used to calculate relevant
conditional probabilities and their corresponding posterior distributions, which allow the calculation of maximum a posteriori (MAP)
estimates and 95% credible intervals (CI95). The analysis was performed using custom-made software written in R (R Development
Core Team, 2015). A similar analysis was performed including only intermediate risk group patients.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession number for the transcriptome sequencing data generated in this study are deposited on Geo bank (reference number:
GSE88905).
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